With transparency becoming a given, pharmacy benefit managers (PBMs) have taken a new approach to marketing their services. The primary marketing/sales strategy for Express Scripts, headquartered in St. Louis, is direct sales with a reliance on intermediary consultants and advisors.
With transparency becoming a given, pharmacy benefit managers (PBMs) have taken a new approach to marketing their services. The primary marketing/sales strategy for Express Scripts, headquartered in St. Louis, is direct sales with a reliance on intermediary consultants and advisors.
The PBM, however, doesn't bank on demographics, but rather sells its assets. Express Scripts, one of the largest PBMs in the country and an independent, emphasizes an educational approach. By educating its potential clients through seminars, conferences, original research on cost drivers and peer-reviewed journal articles, Express Scripts ensures they have enough information to make a good decision.
Joe Eschbacher, senor director, strategic relationship services, says the company will start marketing more aggressively what he considers to be a key differentiator-focusing on the drug mix so that purchasers can realize the lowest net cost.
The company drives quantifiable value and as an independent PBM, avoids conflicts of interest between the revenue stream and cost management.
MARKETING KNOW HOW
Ensuring transparency in a relationship with a PBM, not surprisingly, is the number one issue for most insurers. PBMs offer more advice about what other issues insurers should consider if they are planning to outsource their pharmacy benefits.
The biggest question for clients should be whether a PBM's incentives are aligned with the plan sponsor or plan, says Steve Meholic, president of the Aetna Health PBM.
Byron Mickle, senior vice president, sales, marketing and client services for Navitus Health Solutions, a PBM based in Madison, Wisc., stresses the importance of developing a clinical strategy rather than focusing on rebates.
"There is a lot of money left on the table by not realizing clinical opportunities offered by PBMs," he says, "as well as taking advantage of better buying power."
CIGNA's Chief Medical Officer Claire Marie Burchill, MD, warns plans to search for a PBM that supports integrated data and can deliver total health outcomes.
"You have to take a holistic approach-delivering the right care at the right time at the right place," she says.
"Insurers should be careful to compare apples to apples for prices and programs," adds Kristi Meyer, vice president, marketing and product development, at WellPoint NextRx. "Be attentive to details so that all promised services are delivered. We partner with our clients, listening to their needs and developing tailored solution."
With consolidation in the PBM industry, Jim Hartert, MD, chief medical officer and senior vice president, Prime Therapeutics, Egan, Minn., believes that the pickings are getting slimmer, which makes it more difficult for insurers who want to outsource their PBM services. "It's not a casual decision to outsource; potential clients need a broker or consultant and need to present an request for proposal," he says. "Clients have to look at the scope of services, operations, philosophy, expertise and direction of the PBM to make the best decision.
"Selecting a PBM was easier when it was primarily based on cost but now the emphasis is on utilization, compliance and specialty pharmacy," he adds.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More